Schedule 13G ownership disclosure
Zentalis Pharmaceuticals, Inc.
Common Stock, $0.001 par value per share · CUSIP: 98943L107
Event date: 2025-03-31
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Eventide Asset Management, LLC
Shares: 0.00 · Class: 0%
- Finny Kuruvilla, M.D. Ph. D.
Shares: 0.00 · Class: 0%
- Robin C. John
Shares: 0.00 · Class: 0%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001580642-25-003116
- Form type
- SCHEDULE 13G/A
- Filer
- EVENTIDE ASSET MANAGEMENT, LLC
- CIK
- CIK 1442891
- Filed
- May 14, 2025
- Reporting period
- Mar 31, 2025
- Description
- Schedule 13G beneficial ownership